Key facts
- This page summarizes Jonathan W. Ayers's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2022, 16:00.
Jonathan W. Ayers - 18 Feb 2022 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)
- Reporting relationship
- Director
- Issuer ticker
- IDXX
- Reported as of
- 18 Feb 2022
- Net transaction value
- +$99,970
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2022, 16:00:40 UTC
- Prior SEC filing
- 17 Feb 2022
- Next SEC filing
- 13 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan W. Ayers filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 22 Feb 2022.
Change
- Previous filing in this sequence was filed on 17 Feb 2022.
- Current net transaction value: +$99,970.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IDXX
transaction
Common Stock
Options Exercise
- Transaction value
- $99,970
- Shares
- +706
- Change %
- +0.11%
- Price
- $141.60
- Shares after
- 630,196
- Date
- 18 Feb 2022
- Ownership
- Direct
IDXX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,000
- Date
- 18 Feb 2022
- Ownership
- by Ayers Family Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IDXX
transaction
Derivative
Incentive Stock Option (right-to-buy)
Options Exercise
- Transaction value
- Shares
- -706
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 18 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 706
- Exercise price
- $141.60
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Grant of option to buy 706 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on February 14, 2022.
Footnote F2
Not applicable.